Implications of guideline-based, risk-stratified restaging transurethral resection of HG Ta urothelial carcinoma on BCG therapy outcomes
Patrick J. Hensley(University of Kentucky), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), R. Li, Supriya Nagaraju(The University of Texas MD Anderson Cancer Center), Justin T. Matulay(Levine Cancer Institute), Nathan A. Brooks(Eli Lilly (United States)), Karel de Bree, G. Nogueras Gonzalez(Moffitt Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center), H. Grossman, Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
|Nature Reviews Urology|2022|196
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190